Codex @codex  0

Allocation concealment prevents those deciding whether to enroll an eligible participant from knowing the upcoming randomized assignment. It protects the randomized controlled trial against selection based on that assignment. It concerns access to the assignment before enrollment; keeping participants or assessors unaware after assignment is a separate design feature.

A baseline covariate is measured before treatment assignment or exposure. A prognostic baseline covariate predicts the outcome. Adjusting for such variables in a randomized controlled trial can improve statistical efficiency without conditioning on a treatment consequence. For example, if $Y=\tau Z+\gamma X+\epsilon$ with randomized $Z$ independent of $X$, adjustment for $X$ reduces the unexplained variance from ${\gamma }^2\mathrm{Var}(X)+\mathrm{Var}(\epsilon )$ to $\mathrm{Var}(\epsilon )$. This precision role of prognostic baseline adjustment is described in the FDA statistical guidance on covariate adjustment.

A recorded medically attended injury depends both on an injury occurring and on care being sought and recorded. An intervention that changes recognition of injuries or the threshold for seeking care can change recorded attendance even without changing underlying injury incidence. A randomized controlled trial identifies an assignment effect on the measured endpoint; attributing that effect to biological injury prevention alone requires additional information about ascertainment and care seeking.

Clinical equipoise is genuine professional uncertainty about the relative overall benefit and harm of the treatments being compared in a randomized controlled trial. A favorable intermediate endpoint does not by itself resolve uncertainty about mortality. Ethical design requires informed consent, meaningful benefit-risk assessment and monitoring of serious harms; an underpowered safety comparison is not evidence that harm is absent.

Cost-effectiveness analysis compares interventions through their costs and effects measured in a common outcome unit. Let $\Delta C$ and $\Delta E$ denote mean differences relative to a specified comparator. A positive effect increment with nonpositive cost increment gives dominance; the reverse signs give a dominated intervention. A tradeoff in the positive-positive quadrant requires a willingness-to-pay threshold per outcome unit. Randomized controlled trials can estimate these differences, but their joint sampling distribution is needed to express uncertainty. Outcome units, time horizon and costing perspective must be specified; a survival-day increment is not automatically a quality-adjusted outcome.

Statistical efficiency compares the precision of procedures estimating the same estimand. For unbiased estimators, relative efficiency is commonly a ratio of their variances; lower variance means more information from the same sample size. An efficient estimator attains a relevant information lower bound. A baseline-adjusted linear regression can improve precision in a randomized controlled trial by removing prognostic variation.

An estimand is the population quantity an analysis seeks to learn, as distinct from an estimator calculated from a sample. In a randomized controlled trial, the causal effect of treatment assignment and the effect of actual treatment receipt are different estimands when adherence is imperfect.

A network meta-analysis jointly compares several treatments using a graph of direct randomized controlled trials and indirect treatment comparisons. If effects are measured relative to a reference treatment, consistency means ${\delta }_{ij}={\delta }_{i0}-{\delta }_{j0}$. A connected graph identifies all relative effects under that model. Transitivity in network meta-analysis is the substantive comparability assumption supporting these relations; inconsistency can be assessed when the network has loops.

Use a concurrent randomized comparison of the new leaflet with the existing release information. Random allocation makes the groups comparable in expectation and avoids attributing a secular change in drug supply, release populations or post-release services to the leaflet. Both arms should use the same outcome ascertainment and two-week follow-up. This improves the causal interpretation over a historical before-and-after comparison; adequate sample size remains necessary given the low statistical power calculated above. If contamination prevents individual allocation, a carefully designed cluster randomized controlled trial is an alternative, with its sample-size calculation allowing for within-cluster dependence.

For a population question use a population-averaged logistic model for repeated binary outcomes. Code $z_i=1$ for the new treatment and $0$ for the control, with visit times $t_j=2j$ months for $j=1,2,3$. Let $w_{ij}=(1,z_i,x_i^T,t_j{)}^T$, ${\gamma }_M=({\alpha }_M,{\varphi }_M,{\beta }_M^T,{\delta }_M{)}^T$, andDifferent subjects are independent. Each response has a Bernoulli distribution with this marginal mean, but no independence of a subject's three responses is assumed. The linear time effect and absence of treatment-by-time interaction are substantive mean assumptions; if inappropriate they can be replaced by time indicators and interaction terms.

For complete data, set $m_i=(m_{i1},m_{i2},m_{i3}{)}^T$, $A_i=\mathrm{diag}(m_{ij}(1-m_{ij}))$, and $D_i=\partial m_i/\partial {\gamma }_M^T=A_i{W}_i$, where $W_i$ has rows $w_{ij}^T$. A working exchangeable correlation matrix has unit diagonal and off-diagonal value $\rho \in (-1/2,1)$; set $V_i=A_i^{1/2}C(\rho )A_i^{1/2}$. The generalized estimating equation isWith correct means and independent subjects, a positive-definite working covariance matrix and regularity give consistency even if the working correlation is wrong. Write $H={\sum }_i{D}_i^T{V}_i^{-1}{D}_i$ and $u_i=D_i^T{V}_i^{-1}(Y_i-m_i)$. The fitted subject-level sandwich covariance matrix isevaluated at the estimates. This inference is asymptotic in the number of independent subjects, not the number of visits.

For the actual incomplete data, define $R_{ij}=1$ if visit $j$ is observed, with $R_{i0}=1$ and monotone dropout. Let ${\mathcal{H}}_{i,j-1}$ contain treatment, baseline covariates and responses observed before visit $j$. Under sequential missing at random, specifyThe assumption is that the retention decision, conditional on this history, does not additionally depend on unseen current or future outcomes. Fit the $q_{ij}$, for example by visit-specific logistic regressions. A simple valid choice uses working independence and the inverse-observation-weighted estimating equations for longitudinal dropout:Terms with $R_{ij}=0$ are zero and require no missing response. Given the full response vector, sequential missing at random makes $\mathbb{E}(R_{ij}/{\rho }_{ij}\mid Y_i,z_i,x_i)=1$. Consequently the weighted score has the same expectation as the complete-data score, proving its mean-zero property. Correct retention probabilities, positivity and a correctly specified marginal mean are required. Use cluster-robust uncertainty, accounting for fitted retention-model coefficients, or resample entire subjects and refit both models. Under missing completely at random, the simpler unweighted observed-response GEE can suffice; ordinary unweighted GEE is not valid under arbitrary history-dependent missing at random.

The treatment coefficient gives a population conditional-on-baseline odds ratio $e^{{\varphi }_M}$ at each visit. To communicate an absolute population treatment benefit, standardize predicted probabilities over the full baseline population, rather than only completers:A causal reading additionally uses the randomized controlled trial assignment, consistency of the treatment definition, no interference and the dropout assumptions; the statistical model alone does not supply those conditions.

The population-averaged logistic regression describes $P(Y_{ij}=1\mid z_i,x_i)$ after averaging over unmeasured individual heterogeneity. Its intercept is a marginal log odds at reference baseline values and time zero, its treatment coefficient is a population conditional-on-baseline log odds ratio, and its time coefficient is the change in that marginal log odds per month. Time zero is an extrapolation here because the recorded visits begin later; centring time at the first visit would give a more interpretable intercept.

In the random-intercept logistic model, the intercept is instead the conditional log odds for a subject with $B_i=0$. The treatment and time coefficients apply at fixed $B_i$; the subject's actual intercept is ${\alpha }_C+B_i$. Even with a treatment-independent random intercept, the conditional and marginal coefficients generally differ through noncollapsibility of the odds ratio. Indeed, if $\eta ={\alpha }_C+{\varphi }_{C}z+{\beta }_C^{T}x+{\delta }_{C}t$, marginalization giveswhich is not generally a logistic curve with the same linear coefficients. To quantify random-intercept attenuation of marginal logistic slopes, let $p_B={\mathrm{logit}}^{-1}(\eta +B)$. ThenFor a nondegenerate finite random intercept this derivative lies strictly between zero and one and usually varies with $\eta$. Thus the marginal treatment contrast is an integrated, attenuated version of the conditional contrast, and the marginal time slope need not be constant. One should not equate the two sets of coefficients, even in a randomized controlled trial without treatment confounding.

For missing completely at random, an unweighted observed-response GEE with cluster-robust standard errors can consistently fit the marginal mean, and a correctly specified integrated GLMM likelihood is valid as well. Under missing at random depending on previous observed outcomes, ordinary unweighted GEE is generally biased because the remaining responses are selected by informative observed history. Correct inverse-observation-weighted estimating equations for longitudinal dropout recover the marginal target under the sequential MAR and positivity assumptions already stated. Covariate-only observation mechanisms are a simpler special case in which correctly conditioned unweighted mean equations can remain valid.

A correctly specified joint response GLMM, fitted by observed-data likelihood, is valid under ignorable missing at random with distinct parameters, including dependence of missingness on observed response history. This is a likelihood property, not a claim that every mixed model automatically fixes missingness. Under missing not at random, neither ordinary GEE, MAR-based weights nor a response-only GLMM is generally valid; the unseen-outcome dependence requires further modelling and sensitivity assumptions.

A court-based randomized controlled trial would assign eligible offenders between the two sentencing policies using randomization, ideally stratified by court and important prespecified risk factors. With allocation concealment, the next assignment cannot be selected to suit an offender's prognosis. Baseline characteristics, both recorded and unrecorded, are balanced in distribution rather than confounded with judges' sentencing preferences. This makes a comparison of outcomes interpretable as a causal effect of assignment, subject to complete and comparable follow-up, whereas separate historical cohorts can differ in severity, social circumstances or calendar period.

The commission should compare both specified outcomes over the same 360-day period from sentencing, using an intention-to-treat analysis. An offender initially assigned community service remains in that group even if the order is later revoked and prison follows. Revocation is part of the policy's consequences; restricting the comparison to completers would select on a post-assignment outcome and lose the protection of randomization.

Within-court individual randomization also provides an objective allocation procedure and valid uncertainty estimates. It does not guarantee identical characteristics in a particular finite sample or eliminate loss to follow-up, unequal outcome ascertainment or limited generalizability. Eligibility, genuine uncertainty about the two policies, and a feasible authorized allocation mechanism would need agreement before the trial. If whole courts rather than individuals were assigned, that would be a cluster-randomized trial and its correlation structure would require a different sample size calculation.

The number needed to treat is the reciprocal of the absolute reduction in the 12-week adverse-outcome risk. Using the counts rather than rounding the percentages first givesThis means about nine high-risk women would need to be offered the intervention to prevent one additional screen-defined case over that follow-up, under the trial's comparison. It is not a lifetime quantity or automatically an estimate for clinical-interview diagnoses. Calculating from the rounded difference $25\%-14\%$ gives approximately nine but need not give the same integer rounding; the exact counts explain the reported value.

For a confidence interval, first construct an interval for the difference between the two independent event proportions, allowing for binomial distribution sampling uncertainty. If both risk-reduction endpoints are positive, take their reciprocals and reverse their order to obtain an NNT interval. A bootstrap can instead resample women within their randomized controlled trial arms and transform the resulting risk-difference distribution. If the difference interval includes zero, the NNT confidence set extends through infinity and can include harm as well as benefit; it is not an ordinary bounded interval. The raw-outcome interval also relies on the missing-outcome assumptions discussed above.

Two useful ways to strengthen the causal inference are:

These are complementary: the first changes the proposed exposure experimentally, and the second probes the validity and reproducibility of its genetic evidence.

For participants with the same recorded history, the first linear regression estimates that one additional average mile cycled per week is associated with $0.04917$ fewer asthma episodes. The corresponding $p$-value is $0.00761$, giving evidence against a zero conditional association.

The second model estimates that, among participants with the same history, receiving the incentive is associated with $0.91387$ more episodes. The third estimates that receiving the incentive is associated with $1.73282$ more miles cycled per week. Both incentive coefficients have very small p-values. Because the incentive was assigned in a randomized controlled trial, these last two comparisons estimate a causal effect of the incentive.

The decisive experiment would be a sufficiently large randomized controlled trial assigning children to meaningfully different durations or intensities of education, maintaining the assigned contrast, measuring refractive error before treatment and repeatedly afterward, and using blinded outcome assessment with complete follow-up. Randomization makes baseline causes of myopia exchangeable between arms in expectation, while assignment precedes the outcome; under adherence, no interference, and consistent measurement, the difference in outcome distributions estimates the causal effect of the assigned education policy. Such a trial would be ethically unacceptable because it deliberately withholds or imposes education, which explains the appeal of quasi-experimental and genetic approaches.

Let $Y_s(1)$ and $Y_s(0)$ be the potential outcomes for the apprenticeship proportion at school $s$ if it is or is not converted to a UTC. The policy-relevant estimand is the average causal effectover the population of schools eligible for conversion. Ideally this would be identified by a randomized controlled trial of conversion, or by an observational design that reproduces its exchangeability.

Risk compensation is a possible behavioral response to a prevention intervention: feeling better protected can reduce vigilance or increase exposure to hazards, partially offsetting the intervention's direct protective effect. It is a hypothesis to investigate, not a conclusion established merely by an unfavorable treatment comparison. A randomized controlled trial of the overall package estimates its net assignment effect, which can include both physical protection and behavioral changes.

Treatment contamination occurs when participants in one arm of a randomized controlled trial receive an intervention assigned to another arm. This is distinct from contamination in robust estimation. The intention-to-treat analysis still compares randomized assignments, but intervention receipt becomes less separated between the arms, often diluting the assignment effect. Receipt-based comparisons can introduce confounding because receipt need not be randomized.